Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92


Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis.

Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB.

Clin Infect Dis. 2010 Jul 1;51(1):6-14. doi: 10.1086/653115. Review.


Beyond multidrug-resistant tuberculosis in Europe: a TBNET study.

Günther G, van Leth F, Altet N, Dedicoat M, Duarte R, Gualano G, Kunst H, Muylle I, Spinu V, Tiberi S, Viiklepp P, Lange C; TBNET.

Int J Tuberc Lung Dis. 2015 Dec;19(12):1524-7. doi: 10.5588/ijtld.15.0274.


Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis.

Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH, Kim EK, Lee KM, Lee SS, Park JS, Koh WJ, Lee CH, Shim TS.

Am J Respir Crit Care Med. 2010 Jul 1;182(1):113-9. doi: 10.1164/rccm.200911-1656OC. Epub 2010 Mar 11.


Systematic review of clofazimine for the treatment of drug-resistant tuberculosis.

Gopal M, Padayatchi N, Metcalfe JZ, O'Donnell MR.

Int J Tuberc Lung Dis. 2013 Aug;17(8):1001-7. doi: 10.5588/ijtld.12.0144. Epub 2013 Mar 25. Review.


A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis.

Fofana MO, Shrestha S, Knight GM, Cohen T, White RG, Cobelens F, Dowdy DW.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e00498-16. doi: 10.1128/AAC.00498-16. Print 2017 Mar.


Extensively drug-resistant tuberculosis in california, 1993-2006.

Banerjee R, Allen J, Westenhouse J, Oh P, Elms W, Desmond E, Nitta A, Royce S, Flood J.

Clin Infect Dis. 2008 Aug 15;47(4):450-7. doi: 10.1086/590009.


Extensively and pre-extensively drug resistant tuberculosis in clinical isolates of multi-drug resistant tuberculosis using classical second line drugs (levofloxacin and amikacin).

Mirza IA, Khan FA, Khan KA, Satti L, Ghafoor T, Fayyaz M.

J Coll Physicians Surg Pak. 2015 May;25(5):337-41. doi: 05.2015/JCPSP.337341.


Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.

Kwon YS, Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, Choi YS, Kim K, Kim J, Shim YM, Koh WJ.

Clin Infect Dis. 2008 Aug 15;47(4):496-502. doi: 10.1086/590005.


Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.

Centers for Disease Control and Prevention (CDC).

MMWR Recomm Rep. 2009 Feb 13;58(RR-3):1-43.


Therapy Of XDR TB with thioridazine a drug beyond patent protection but eligible for patent "as new use".

Amaral L, Molnar J.

Recent Pat Antiinfect Drug Discov. 2010 Jun;5(2):109-14.


Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis.

Blöndal K, Viiklepp P, Guðmundsson LJ, Altraja A.

Int J Tuberc Lung Dis. 2012 Sep;16(9):1228-33. doi: 10.5588/ijtld.12.0037. Epub 2012 Jun 28.


Partial extensively drug resistance (XDR) tuberculosis in children.

Shah I, Rahangdale A.

Indian Pediatr. 2011 Dec;48(12):977-9.


Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis.

Migliori GB, Sotgiu G, Gandhi NR, Falzon D, DeRiemer K, Centis R, Hollm-Delgado MG, Palmero D, Pérez-Guzmán C, Vargas MH, D'Ambrosio L, Spanevello A, Bauer M, Chan ED, Schaaf HS, Keshavjee S, Holtz TH, Menzies D; “The Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB”.

Eur Respir J. 2013 Jul;42(1):169-179. doi: 10.1183/09031936.00136312. Epub 2012 Oct 11.


Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience.

Liu CH, Li L, Chen Z, Wang Q, Hu YL, Zhu B, Woo PC.

PLoS One. 2011 Apr 29;6(4):e19399. doi: 10.1371/journal.pone.0019399.


Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012.

Chang KC, Yew WW.

Respirology. 2013 Jan;18(1):8-21. doi: 10.1111/j.1440-1843.2012.02257.x. Review.


Multidrug- and extensively drug-resistant tuberculosis, Germany.

Eker B, Ortmann J, Migliori GB, Sotgiu G, Muetterlein R, Centis R, Hoffmann H, Kirsten D, Schaberg T, Ruesch-Gerdes S, Lange C; German TBNET Group.

Emerg Infect Dis. 2008 Nov;14(11):1700-6. doi: 10.3201/eid1411.080729.


Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a Medical Center in Taiwan.

Lai CC, Tan CK, Huang YT, Chou CH, Hung CC, Yang PC, Luh KT, Hsueh PR.

Clin Infect Dis. 2008 Oct 1;47(7):e57-63. doi: 10.1086/591702.


Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007.

Marks SM, Flood J, Seaworth B, Hirsch-Moverman Y, Armstrong L, Mase S, Salcedo K, Oh P, Graviss EA, Colson PW, Armitige L, Revuelta M, Sheeran K; TB Epidemiologic Studies Consortium.

Emerg Infect Dis. 2014 May;20(5):812-21. doi: 10.3201/eid2005.131037.

Supplemental Content

Support Center